Symbols / RLYB Stock $8.55 +3.14% Rallybio Corporation
RLYB (Stock) Chart
About
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Stock Fundamentals
Scroll to Statements| Market Cap | 45.23M | Enterprise Value | -9.33M | Income | -8.98M | Sales | 858.00K | Book/sh | 10.97 | Cash/sh | 10.35 |
| Dividend Yield | — | Payout | 0.00% | Employees | 14 | IPO | — | P/E | — | Forward P/E | -1.58 |
| PEG | — | P/S | 52.71 | P/B | 0.78 | P/C | — | EV/EBITDA | 0.30 | EV/Sales | -10.88 |
| Quick Ratio | 12.96 | Current Ratio | 14.51 | Debt/Eq | 0.30 | LT Debt/Eq | — | EPS (ttm) | -1.59 | EPS next Y | -5.40 |
| EPS Growth | — | Revenue Growth | 4.84% | Earnings | 2026-03-16 | ROA | -30.07% | ROE | -15.01% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -28.88% | Profit Margin | 0.00% | Shs Outstand | 5.29M | Shs Float | 3.16M | Short Float | 25.22% |
| Short Ratio | 3.67 | Short Interest | — | 52W High | 11.49 | 52W Low | 2.16 | Beta | -1.20 | Avg Volume | 144.02K |
| Volume | 22.46K | Target Price | — | Recom | Hold | Prev Close | $8.29 | Price | $8.55 | Change | 3.14% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-15 | down | Jones Trading | Buy → Hold | — |
| 2025-04-09 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-02-12 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-01-13 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-12-03 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-22 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-08 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-10-30 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-10-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-08-26 | main | Evercore ISI Group | Outperform → Outperform | $15 |
| 2024-08-12 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-15 | down | JP Morgan | Overweight → Neutral | — |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-04-19 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2024-04-18 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2024-04-11 | main | Wedbush | Outperform → Outperform | $11 |
| 2024-03-13 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2024-03-13 | main | HC Wainwright & Co. | Buy → Buy | $9 |
- Rallybio Corporation (RLYB) Sector Rotation | Rallybio Corporation notches 13.9% EPS beat on narrower loss - Restructuring - UBND thành phố Hải Phòng Wed, 22 Apr 2026 22
- RLYB Stock Chart | RALLYBIO CORP (NASDAQ:RLYB) - ChartMill Fri, 10 Apr 2026 07
- J&J (NYSE: JNJ) discloses 152,901‑share stake in Rallybio (RLYB) - Stock Titan Mon, 13 Apr 2026 07
- Rallybio Announces Reverse Stock Split of Common Stock - Yahoo Finance ue, 03 Feb 2026 08
- Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders? - Morningstar Mon, 06 Apr 2026 07
- Rallybio CMO Departs Amid Pending Candid Therapeutics Merger - The Globe and Mail Wed, 01 Apr 2026 07
- Will Rallybio Corporation (RLYB) Stock Outperform S&P 500 | Price at $8.24, Down 2.31% - Risk Management - Cổng thông tin điện tử tỉnh Lào Cai Mon, 13 Apr 2026 07
- Rallybio to Merge With Candid Therapeutics; Candid Holders to Own ~57.6% of Combined Company - TradingView Mon, 02 Mar 2026 08
- Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Benzinga Mon, 02 Mar 2026 08
- RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders - The AI Journal Mon, 02 Mar 2026 15
- Rallybio Corporation (RLYB) Stock: Price Structure (Hovering) 2026-04-16 - Collaborative Trading Signals - Cổng thông tin điện tử tỉnh Lào Cai hu, 16 Apr 2026 19
- Rallybio (RLYB) CMO Steven Ryder exits as Candid Therapeutics merger proceeds - Stock Titan ue, 31 Mar 2026 07
- Is Rallybio Corporation (RLYB) Stock cyclical or stable | Price at $8.43, Up 0.36% - Stock Analysis Community - Xã Vĩnh Công hu, 02 Apr 2026 07
- Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? - Stock Titan Fri, 06 Mar 2026 08
- Is Rallybio Corporation (RLYB) Stock Cheap at Current Price | Price at $8.29, Down 1.60% - Shared Momentum Picks - Cổng thông tin điện tử tỉnh Lào Cai Mon, 06 Apr 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.86
+34.91%
|
0.64
|
0.00
|
0.00
|
| Operating Revenue |
|
0.86
+34.91%
|
0.64
|
0.00
|
0.00
|
| Operating Expense |
|
33.92
-44.51%
|
61.13
-22.55%
|
78.93
+16.27%
|
67.88
|
| Research And Development |
|
19.60
-52.79%
|
41.51
-22.48%
|
53.54
+31.59%
|
40.69
|
| Selling General And Administration |
|
14.32
-27.01%
|
19.62
-22.70%
|
25.39
-6.64%
|
27.20
|
| General And Administrative Expense |
|
14.32
-27.01%
|
19.62
-22.70%
|
25.39
-6.64%
|
27.20
|
| Other Gand A |
|
14.32
-27.01%
|
19.62
-22.70%
|
25.39
-6.64%
|
27.20
|
| Total Expenses |
|
33.92
-44.51%
|
61.13
-22.55%
|
78.93
+16.27%
|
67.88
|
| Operating Income |
|
-33.06
+45.35%
|
-60.50
+23.36%
|
-78.93
-16.27%
|
-67.88
|
| Total Operating Income As Reported |
|
-33.06
+45.35%
|
-60.50
+23.36%
|
-78.93
-16.27%
|
-67.88
|
| EBITDA |
|
-32.97
+45.38%
|
-60.37
+23.38%
|
-78.78
-16.34%
|
-67.72
|
| Normalized EBITDA |
|
-32.97
+45.38%
|
-60.37
+23.38%
|
-78.78
-16.34%
|
-67.72
|
| Reconciled Depreciation |
|
0.09
-29.77%
|
0.13
-12.67%
|
0.15
-10.18%
|
0.17
|
| EBIT |
|
-33.06
+45.35%
|
-60.50
+23.36%
|
-78.93
-16.27%
|
-67.88
|
| Net Income |
|
-8.98
+84.46%
|
-57.77
+22.52%
|
-74.56
-11.87%
|
-66.65
|
| Pretax Income |
|
-8.98
+84.46%
|
-57.77
+22.52%
|
-74.56
-11.87%
|
-66.65
|
| Net Non Operating Interest Income Expense |
|
2.19
-48.08%
|
4.22
-31.41%
|
6.15
+213.14%
|
1.96
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.00
|
| Net Interest Income |
|
2.19
-48.08%
|
4.22
-31.41%
|
6.15
+213.14%
|
1.96
|
| Interest Expense |
|
—
|
—
|
—
|
0.00
|
| Interest Income Non Operating |
|
2.19
-48.08%
|
4.22
-31.41%
|
6.15
+213.14%
|
1.96
|
| Interest Income |
|
2.19
-48.08%
|
4.22
-31.41%
|
6.15
+213.14%
|
1.96
|
| Other Income Expense |
|
21.90
+1564.68%
|
-1.50
+15.96%
|
-1.78
-142.70%
|
-0.73
|
| Other Non Operating Income Expenses |
|
22.77
+2960.62%
|
0.74
+183.97%
|
0.26
-23.39%
|
0.34
|
| Tax Provision |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.98
+84.46%
|
-57.77
+22.52%
|
-74.56
-11.87%
|
-66.65
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.98
+84.46%
|
-57.77
+22.52%
|
-74.56
-11.87%
|
-66.65
|
| Net Income From Continuing And Discontinued Operation |
|
-8.98
+84.46%
|
-57.77
+22.52%
|
-74.56
-11.87%
|
-66.65
|
| Net Income Continuous Operations |
|
-8.98
+84.46%
|
-57.77
+22.52%
|
-74.56
-11.87%
|
-66.65
|
| Normalized Income |
|
-8.98
+84.46%
|
-57.77
+22.52%
|
-74.56
-11.87%
|
-66.65
|
| Net Income Common Stockholders |
|
-8.98
+84.46%
|
-57.77
+22.52%
|
-74.56
-11.87%
|
-66.65
|
| Diluted EPS |
|
-1.59
+85.06%
|
-10.64
+27.72%
|
-14.72
+11.96%
|
-16.72
|
| Basic EPS |
|
-1.59
+85.06%
|
-10.64
+27.72%
|
-14.72
+11.96%
|
-16.72
|
| Basic Average Shares |
|
5.63
+3.42%
|
5.44
+7.66%
|
5.06
+27.11%
|
3.98
|
| Diluted Average Shares |
|
5.63
+3.42%
|
5.44
+7.66%
|
5.06
+27.11%
|
3.98
|
| Diluted NI Availto Com Stockholders |
|
-8.98
+84.46%
|
-57.77
+22.52%
|
-74.56
-11.87%
|
-66.65
|
| Earnings From Equity Interest |
|
-0.87
+60.96%
|
-2.24
-9.70%
|
-2.04
-89.86%
|
-1.07
|
| Earnings From Equity Interest Net Of Tax |
|
—
|
—
|
—
|
-1.07
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
62.26
-8.58%
|
68.11
-41.09%
|
115.62
-35.92%
|
180.44
|
| Current Assets |
|
61.25
-9.71%
|
67.84
-40.90%
|
114.79
-36.05%
|
179.50
|
| Cash Cash Equivalents And Short Term Investments |
|
54.74
-16.45%
|
65.51
-40.41%
|
109.93
-34.95%
|
168.99
|
| Cash And Cash Equivalents |
|
31.37
+125.66%
|
13.90
-43.24%
|
24.49
-57.00%
|
56.96
|
| Other Short Term Investments |
|
23.36
-54.73%
|
51.61
-39.59%
|
85.44
-23.74%
|
112.04
|
| Prepaid Assets |
|
4.00
+199.63%
|
1.33
-52.42%
|
2.81
-70.31%
|
9.45
|
| Other Current Assets |
|
2.52
+152.96%
|
0.99
-51.56%
|
2.05
+95.62%
|
1.05
|
| Total Non Current Assets |
|
1.01
+277.53%
|
0.27
-67.87%
|
0.83
-11.50%
|
0.94
|
| Net PPE |
|
0.20
-25.84%
|
0.27
-54.90%
|
0.59
-34.87%
|
0.91
|
| Gross PPE |
|
0.68
-26.38%
|
0.92
-17.40%
|
1.11
-13.03%
|
1.28
|
| Accumulated Depreciation |
|
-0.48
+26.61%
|
-0.65
-25.05%
|
-0.52
-40.21%
|
-0.37
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.17
+15.13%
|
0.15
-56.07%
|
0.35
-33.97%
|
0.52
|
| Machinery Furniture Equipment |
|
0.36
-17.40%
|
0.43
+0.00%
|
0.43
+2.62%
|
0.42
|
| Construction In Progress |
|
—
|
—
|
—
|
0.00
|
| Other Properties |
|
—
|
—
|
—
|
0.52
|
| Leases |
|
0.15
-56.51%
|
0.34
+0.00%
|
0.34
+0.00%
|
0.34
|
| Investments And Advances |
|
—
|
0.00
-100.00%
|
0.24
+696.67%
|
0.03
|
| Long Term Equity Investment |
|
—
|
0.00
-100.00%
|
0.24
+696.67%
|
0.03
|
| Other Non Current Assets |
|
0.81
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
4.30
-33.30%
|
6.45
-31.60%
|
9.44
-15.13%
|
11.12
|
| Current Liabilities |
|
4.22
-32.35%
|
6.24
-32.61%
|
9.26
-13.78%
|
10.74
|
| Payables And Accrued Expenses |
|
1.58
-26.20%
|
2.15
-63.51%
|
5.88
+0.31%
|
5.86
|
| Payables |
|
0.13
-54.68%
|
0.28
-71.52%
|
0.98
-12.39%
|
1.11
|
| Accounts Payable |
|
0.13
-54.68%
|
0.28
-71.52%
|
0.98
-12.39%
|
1.11
|
| Current Accrued Expenses |
|
1.46
-21.96%
|
1.87
-61.91%
|
4.90
+3.29%
|
4.75
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.33
-24.59%
|
3.10
-2.24%
|
3.17
-32.68%
|
4.70
|
| Current Debt And Capital Lease Obligation |
|
0.09
-38.96%
|
0.15
-29.68%
|
0.22
+20.99%
|
0.18
|
| Current Capital Lease Obligation |
|
0.09
-38.96%
|
0.15
-29.68%
|
0.22
+20.99%
|
0.18
|
| Current Deferred Liabilities |
|
0.21
-75.00%
|
0.85
|
0.00
|
—
|
| Current Deferred Revenue |
|
0.21
-75.00%
|
0.85
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.08
-61.32%
|
0.21
+22.54%
|
0.17
-53.74%
|
0.37
|
| Long Term Debt And Capital Lease Obligation |
|
0.08
|
0.00
-100.00%
|
0.17
-53.74%
|
0.37
|
| Long Term Capital Lease Obligation |
|
0.08
|
0.00
-100.00%
|
0.17
-53.74%
|
0.37
|
| Non Current Deferred Liabilities |
|
0.00
-100.00%
|
0.21
|
0.00
|
—
|
| Non Current Deferred Revenue |
|
0.00
-100.00%
|
0.21
|
0.00
|
—
|
| Stockholders Equity |
|
57.96
-6.00%
|
61.65
-41.94%
|
106.18
-37.29%
|
169.32
|
| Common Stock Equity |
|
57.96
-6.00%
|
61.65
-41.94%
|
106.18
-37.29%
|
169.32
|
| Capital Stock |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Common Stock |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
5.28
+1.82%
|
5.19
+9.73%
|
4.73
-0.02%
|
4.73
|
| Ordinary Shares Number |
|
5.28
+1.82%
|
5.19
+9.73%
|
4.73
-0.02%
|
4.73
|
| Additional Paid In Capital |
|
359.93
+1.50%
|
354.60
+3.86%
|
341.41
+3.39%
|
330.21
|
| Retained Earnings |
|
-302.00
-3.06%
|
-293.02
-24.56%
|
-235.25
-46.40%
|
-160.68
|
| Gains Losses Not Affecting Retained Earnings |
|
0.02
-73.53%
|
0.07
+353.33%
|
0.01
+107.01%
|
-0.21
|
| Other Equity Adjustments |
|
0.02
-73.53%
|
0.07
+353.33%
|
0.01
+107.01%
|
-0.21
|
| Total Equity Gross Minority Interest |
|
57.96
-6.00%
|
61.65
-41.94%
|
106.18
-37.29%
|
169.32
|
| Total Capitalization |
|
57.96
-6.00%
|
61.65
-41.94%
|
106.18
-37.29%
|
169.32
|
| Working Capital |
|
57.03
-7.42%
|
61.60
-41.63%
|
105.53
-37.47%
|
168.75
|
| Invested Capital |
|
57.96
-6.00%
|
61.65
-41.94%
|
106.18
-37.29%
|
169.32
|
| Total Debt |
|
0.18
+14.29%
|
0.15
-60.71%
|
0.39
-29.37%
|
0.56
|
| Capital Lease Obligations |
|
0.18
+14.29%
|
0.15
-60.71%
|
0.39
-29.37%
|
0.56
|
| Net Tangible Assets |
|
57.96
-6.00%
|
61.65
-41.94%
|
106.18
-37.29%
|
169.32
|
| Tangible Book Value |
|
57.96
-6.00%
|
61.65
-41.94%
|
106.18
-37.29%
|
169.32
|
| Investmentsin Joint Venturesat Cost |
|
—
|
0.00
-100.00%
|
0.24
+696.67%
|
0.03
|
| Non Current Accrued Expenses |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-29.81
+39.51%
|
-49.28
+18.22%
|
-60.27
-5.20%
|
-57.28
|
| Cash Flow From Continuing Operating Activities |
|
-29.81
+39.51%
|
-49.28
+18.22%
|
-60.27
-5.20%
|
-57.28
|
| Net Income From Continuing Operations |
|
-8.98
+84.46%
|
-57.77
+22.52%
|
-74.56
-11.87%
|
-66.65
|
| Depreciation Amortization Depletion |
|
0.09
-29.77%
|
0.13
-12.67%
|
0.15
-10.18%
|
0.17
|
| Depreciation And Amortization |
|
0.09
-29.77%
|
0.13
-12.67%
|
0.15
-10.18%
|
0.17
|
| Other Non Cash Items |
|
-0.57
+64.45%
|
-1.61
+47.81%
|
-3.09
-610.11%
|
-0.43
|
| Stock Based Compensation |
|
5.31
-33.52%
|
7.99
-26.80%
|
10.92
+14.96%
|
9.50
|
| Operating Gains Losses |
|
-21.48
-1059.18%
|
2.24
+9.70%
|
2.04
+89.86%
|
1.07
|
| Change In Working Capital |
|
-4.19
-1524.81%
|
-0.26
-106.03%
|
4.28
+556.94%
|
-0.94
|
| Change In Prepaid Assets |
|
-2.04
-175.00%
|
2.72
-53.19%
|
5.82
+225.27%
|
-4.64
|
| Change In Payables And Accrued Expense |
|
-1.30
+67.81%
|
-4.04
-162.13%
|
-1.54
-141.57%
|
3.71
|
| Change In Accrued Expense |
|
-1.15
+65.64%
|
-3.34
-131.74%
|
-1.44
-144.79%
|
3.22
|
| Change In Payable |
|
-0.15
+78.22%
|
-0.70
-605.05%
|
-0.10
-120.33%
|
0.49
|
| Change In Account Payable |
|
-0.15
+78.22%
|
-0.70
-605.05%
|
-0.10
-120.33%
|
0.49
|
| Change In Other Working Capital |
|
-0.85
-180.00%
|
1.06
|
—
|
—
|
| Investing Cash Flow |
|
47.27
+41.13%
|
33.49
+21.09%
|
27.66
+124.66%
|
-112.17
|
| Cash Flow From Continuing Investing Activities |
|
47.27
+41.13%
|
33.49
+21.09%
|
27.66
+124.66%
|
-112.17
|
| Net PPE Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.01
+77.78%
|
-0.05
|
| Purchase Of PPE |
|
—
|
0.00
+100.00%
|
-0.01
+77.78%
|
-0.05
|
| Capital Expenditure |
|
—
|
—
|
-0.01
+77.78%
|
-0.05
|
| Net Investment Purchase And Sale |
|
28.77
-18.95%
|
35.49
+18.62%
|
29.92
+126.76%
|
-111.82
|
| Purchase Of Investment |
|
-17.70
+63.83%
|
-48.93
+54.86%
|
-108.41
+46.15%
|
-201.32
|
| Sale Of Investment |
|
46.47
-44.96%
|
84.42
-38.97%
|
138.33
+54.56%
|
89.50
|
| Net Business Purchase And Sale |
|
18.50
+1025.00%
|
-2.00
+11.11%
|
-2.25
-650.00%
|
-0.30
|
| Purchase Of Business |
|
-1.50
+25.00%
|
-2.00
+11.11%
|
-2.25
-650.00%
|
-0.30
|
| Gain Loss On Sale Of Business |
|
-22.35
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
0.02
-99.69%
|
5.20
+3535.66%
|
0.14
-99.72%
|
51.08
|
| Cash Flow From Continuing Financing Activities |
|
0.02
-99.69%
|
5.20
+3535.66%
|
0.14
-99.72%
|
51.08
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
5.41
|
0.00
-100.00%
|
51.53
|
| Proceeds From Stock Option Exercised |
|
0.02
-74.19%
|
0.06
-78.01%
|
0.28
+18.49%
|
0.24
|
| Net Other Financing Charges |
|
—
|
-0.27
-92.81%
|
-0.14
+79.94%
|
-0.69
|
| Changes In Cash |
|
17.47
+264.96%
|
-10.59
+67.38%
|
-32.46
+72.58%
|
-118.38
|
| Beginning Cash Position |
|
13.90
-43.24%
|
24.49
-57.00%
|
56.96
-67.51%
|
175.33
|
| End Cash Position |
|
31.37
+125.66%
|
13.90
-43.24%
|
24.49
-57.00%
|
56.96
|
| Free Cash Flow |
|
-29.81
+39.51%
|
-49.28
+18.24%
|
-60.28
-5.13%
|
-57.34
|
| Common Stock Issuance |
|
0.00
-100.00%
|
5.41
|
0.00
-100.00%
|
51.53
|
| Earnings Losses From Equity Investments |
|
0.87
-60.96%
|
2.24
+9.70%
|
2.04
+89.86%
|
1.07
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
5.41
|
0.00
-100.00%
|
51.53
|
| Sale Of Business |
|
20.00
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-31 View
- 10-K2026-03-16 View
- 8-K2026-03-02 View
- 42026-02-23 View
- 42026-02-20 View
- 42026-02-20 View
- 8-K2026-01-29 View
- 10-Q2025-11-06 View
- 8-K2025-11-06 View
- 8-K2025-08-29 View
- 10-Q2025-08-07 View
- 8-K2025-08-07 View
- 8-K2025-07-08 View
- 8-K2025-06-27 View
- 8-K2025-05-16 View
- 42025-05-15 View
- 42025-05-15 View
- 42025-05-15 View
- 42025-05-15 View
- 42025-05-15 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|